You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PA-20-047: Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)

    Release Date: 01-08-2020Open Date: 03-05-2020 Due Dates: Multiple Close Date: 01-06-2023

    Background Single cell analysis has recently become an active area of research to uncover fundamental biological principles behind cell diversity, which are often masked and not amenable to the population analysis of cells. The past several years have witnessed a rapid advancement in the development of single cell technologies and analysis methods. Multiple single cell "-omics" approaches are eme ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PAR-20-111: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 03-02-2020Open Date: 07-11-2020 Due Dates: Multiple Close Date: 05-08-2023

    A. Overview Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. However, before a new chemical entity can be tested in a clinical setting, it must undergo a process of chemical optimization to improve potency, selectivity, and drug-like properties, followed by pre-clinical safety testing to meet the standards set by the Food a ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

    Release Date: 11-16-2021Open Date: 01-28-2022 Due Dates: Multiple Close Date: 02-29-2024

    Since its inception in 1982, the NIH SBIR program has provided the small business community with seed funding to support the development of a broad array of commercial products to detect, diagnose, treat, and prevent disease.? It provides an important funding mechanism for bringing new interventions to patients and clinicians. The SBIR program is structured in three phases. The objective in Phase ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

    Release Date: 11-16-2021Open Date: 01-28-2022 Due Dates: Multiple Close Date: 02-29-2024

    Since its inception in 1982, the NIH SBIR program has provided the small business community with seed funding to support the development of a broad array of commercial products to detect, diagnose, treat, and prevent disease. It provides an important funding mechanism for bringing new interventions to patients and clinicians. The SBIR program is structured in three phases. The objective in Phase I ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-22-102: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)

    Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024

    Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-DA-23-021: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44- Clinical Trial Optional)

    Release Date: 03-28-2022Open Date: 07-15-2022 Due Dates: Multiple Close Date: 02-14-2025

    According to the Centers for Disease Control and Prevention (CDC), more than 100,000 deaths from overdose were reported from April 2020 to April 2021 alone. Data shows an increase in overdoses due to natural and semi-synthetic opioids, synthetic opioids, predominantly fentanyl, and psychostimulants, such as methamphetamine or cocaine. In fact, in the year ending in April 2021, fentanyl was the lea ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PA-22-176: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

    Release Date: 06-02-2022Open Date: 08-05-2022 Due Dates: Multiple Close Date: 04-06-2023

    The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs enable US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization. Nation ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. PA-22-177: PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

    Release Date: 06-02-2022Open Date: 08-05-2022 Due Dates: Multiple Close Date: 04-06-2023

    The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs enable US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization. Nation ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PA-22-178: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

    Release Date: 06-02-2022Open Date: 08-05-2022 Due Dates: Multiple Close Date: 04-06-2023

    The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs enable US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization. Nation ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PA-22-179: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

    Release Date: 06-02-2022Open Date: 08-05-2022 Due Dates: Multiple Close Date: 04-06-2023

    The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs enable US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization. Nation ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government